Home  /   Products  /   Antiallergic  /   Betahistine 16 mg – [30 tablets]

Betahistine 16 mg – [30 tablets]


A drug that improves the microcirculation of the labyrinth, used in the pathology of the vestibular apparatus

SKU: 61094 Category:


Betahistine Pharmacodynamics
Betahistine acts mainly on the histamine H1 and H3 receptors of the inner ear and vestibular nuclei of the central nervous system. Through direct agonist effect on H-receptors of the inner ear vessels, as well as indirectly on H3-histamine receptors of the vestibular nuclei of the central nervous system (CNS); it improves microcirculation and capillary permeability, normalizes the endolymph pressure in the labyrinth and cochlea. At the same time, betahistine increases blood flow in the basillary artery. It accelerates
recovery of vestibular function after unilateral vestibular neurectomy, accelerating and facilitating central vestibular compensation (due to antagonism with H3-histamine receptors). It has a pronounced central effect, being an inhibitor of H3-receptor nuclei of the vestibular nerve. It dose-dependently reduces the generation of action potentials in the neurons of the lateral and medial vestibular nuclei.
It relieves symptoms of Meniere’s syndrome and vestibular vertigo. Stable therapeutic effect occurs after 14 days.

– Treatment of Meniere’s syndrome, characterized by dizziness
(accompanied by nausea and vomiting), decreased hearing and tinnitus.
* Symptomatic treatment of vestibular vertigo (vertigo).

Hypersensitivity to any of the drug components, pregnancy and lactation (due to lack of data). Childhood. Lactose intolerance, lactase deficiency and glucose-gapactose malabsorption syndrome.
With caution.
Gastric or 12 duodenal ulcer
Gastric or 12 duodenal ulcer (including anamnesis), pheochromo-cytoma, bronchial asthma. These patients should be regularly monitored during the treatment period.
Pregnancy and lactation
There are not enough data to estimate the drug effect during pregnancy and lactation. Therefore, it is not recommended to use during pregnancy. Breast-feeding should be stopped during the treatment period.

Dosage and administration

  • Orally, with meals.
  • Tablets 8 mg: 1-2 tablets 3 times a day. Tablets 16 mg: 14-1 tablets 3 times a day.
  • Improvement is usually noticed at the beginning of therapy; stable therapeutic effect occurs after two weeks of treatment and may increase during several months of treatment. Treatment is long. The duration of drug intake is chosen individually.